Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 50 Melanoma 23 Neoplasms 19 Neoplasm Metastasis 19 Squamous Cell Carcinoma of Head and Neck 17 Lung Neoplasms 13 Skin Neoplasms 12 Recurrence 10 Head and Neck Neoplasms 10 Carcinoma, Renal Cell 9 Prostatic Neoplasms 8 Ovarian Neoplasms 8 Colorectal Neoplasms 8 Carcinoma, Squamous Cell 8 Carcinoma, Basal Cell 8 Breast Neoplasms 8 Urinary Bladder Neoplasms 7 Carcinoma, Merkel Cell 7 Triple Negative Breast Neoplasms 6 Colonic Neoplasms 6 Carcinoma 6 Adenocarcinoma 6 Uterine Cervical Neoplasms 5 Sarcoma 5 Pancreatic Neoplasms 5 Glioblastoma 5 Stomach Neoplasms 4 Multiple Myeloma 4 Mouth Neoplasms 4 Fallopian Tube Neoplasms 4

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 aflutinib 9 Drug Therapy 9 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × cemiplimab × Clear all

NCT06865339 2026-04-13

TRIPL

Montefiore Medical Center

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡